Summary:
In patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus, combined treatment with metformin and ezetimibe significantly improved PPAR-gamma and adiponectin gene expression and biochemical parameters compared to metformin monotherapy,
though it was associated with mild, manageable side effects without severe adverse events.
| PICO | Description |
|---|---|
| Population | Adult patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) concomitant with type 2 diabetes mellitus. |
| Intervention | Combined therapy of metformin plus ezetimibe administered for six months (Met + EZY group). |
| Comparison | Metformin monotherapy for six months (Met group). |
| Outcome | Combined metformin and ezetimibe significantly enhanced expression of PPAR-gamma and adiponectin genes, improved biochemical markers relevant to liver function and glucose metabolism compared to metformin alone. Side effects were mild and manageable with no serious adverse events reported. |
Source: Asiyeh Masaeli. “Combined effect of metformin and ezetimibe on PPAR-gamma and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes.” Read article here.
